Radiation Dosimetry Results From a Phase II Trial of Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy for Patients With Non-Hodgkin's Lymphoma and Mild Thrombocytopenia
Cancer Biotherapy and Radiopharmaceuticals | May 21, 2003 | Volume: 18 | Issue: 2 | Pages: 165-178
10.1089/108497803765036337
| PMID 12804042